Exact Mass: 423.33617860000004

Exact Mass Matches: 423.33617860000004

Found 141 metabolites which its exact mass value is equals to given mass value 423.33617860000004, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

alpha-Tocotrienoxyl radical

2,5,7,8-tetramethyl-6-oxo-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]-3,4,6,8a-tetrahydro-2H-1-benzopyran-8a-yl

C29H43O2 (423.3262878)


This compound belongs to the family of Diterpenes. These are terpene compounds formed by four isoprene units.

   

O-Linoleoylcarnitine

3-[(9Z,12Z)-Octadeca-9,12-dienoyloxy]-4-(trimethylammonio)butanoic acid

C25H45NO4 (423.33484100000004)


O-Linoleoylcarnitine is an acylcarnitine. More specifically, it is an linoleic ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. O-Linoleoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine O-Linoleoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular O-Linoleoylcarnitine is elevated in the blood or plasma of individuals with Parkinson disease (PMID: 29294246), chronic heart failure (PMID: 26796394, PMID: 27473038), carnitine/acylcarnitine translocase (CACT) deficiency (PMID: 15057979 ), and ischaemia/reperfusion (PMID: 26936967, PMID: 22607863, PMID: 24468136). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(10Z,12Z)-octadeca-10,12-dienoylcarnitine

3-(octadeca-10,12-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C25H45NO4 (423.33484100000004)


(10Z,12Z)-octadeca-10,12-dienoylcarnitine is an acylcarnitine. More specifically, it is an (10Z,12Z)-octadeca-10,12-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (10Z,12Z)-octadeca-10,12-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (10Z,12Z)-octadeca-10,12-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(9Z,11E)-Octadeca-9,11-dienoylcarnitine

3-(Octadeca-9,11-dienoyloxy)-4-(trimethylazaniumyl)butanoic acid

C25H45NO4 (423.33484100000004)


(9Z,11E)-octadeca-9,11-dienoylcarnitine is an acylcarnitine. More specifically, it is an (9Z,11E)-octadeca-9,11-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9Z,11E)-octadeca-9,11-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9Z,11E)-octadeca-9,11-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (9Z,11E)-octadeca-9,11-dienoylcarnitine is elevated in the blood or plasma of individuals with Parkinson disease (PMID: 29294246), chronic heart failure (PMID: 26796394, PMID: 27473038), carnitine/acylcarnitine translocase (CACT) deficiency (PMID: 15057979 ), and ischaemia/reperfusion (PMID: 26936967, PMID: 22607863, PMID: 24468136). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(6Z,9Z)-Octadeca-6,9-dienoylcarnitine

3-(octadeca-6,9-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C25H45NO4 (423.33484100000004)


(6Z,9Z)-octadeca-6,9-dienoylcarnitine is an acylcarnitine. More specifically, it is an (6Z,9Z)-octadeca-6,9-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6Z,9Z)-octadeca-6,9-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (6Z,9Z)-octadeca-6,9-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (6Z,9Z)-octadeca-6,9-dienoylcarnitine is elevated in the blood or plasma of individuals with Parkinson disease (PMID: 29294246), chronic heart failure (PMID: 26796394, PMID: 27473038), carnitine/acylcarnitine translocase (CACT) deficiency (PMID: 15057979 ), and ischaemia/reperfusion (PMID: 26936967, PMID: 22607863, PMID: 24468136). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2E,4E)-Octadeca-2,4-dienoylcarnitine

3-(octadeca-2,4-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C25H45NO4 (423.33484100000004)


(2E,4E)-octadeca-2,4-dienoylcarnitine is an acylcarnitine. More specifically, it is an (2E,4E)-octadeca-2,4-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,4E)-octadeca-2,4-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (2E,4E)-octadeca-2,4-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (2E,4E)-octadeca-2,4-dienoylcarnitine is elevated in the blood or plasma of individuals with Parkinson disease (PMID: 29294246), chronic heart failure (PMID: 26796394, PMID: 27473038), carnitine/acylcarnitine translocase (CACT) deficiency (PMID: 15057979 ), and ischaemia/reperfusion (PMID: 26936967, PMID: 22607863, PMID: 24468136). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

9-(3-Methyl-5-propylfuran-2-yl)nonanoylcarnitine

3-{[9-(3-methyl-5-propylfuran-2-yl)nonanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C24H41NO5 (423.29845760000006)


9-(3-methyl-5-propylfuran-2-yl)nonanoylcarnitine is an acylcarnitine. More specifically, it is an 9-(3-methyl-5-propylfuran-2-yl)nonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-(3-methyl-5-propylfuran-2-yl)nonanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 9-(3-methyl-5-propylfuran-2-yl)nonanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-(5-Heptyl-3-methylfuran-2-yl)pentanoylcarnitine

3-{[5-(5-heptyl-3-methylfuran-2-yl)pentanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C24H41NO5 (423.29845760000006)


5-(5-heptyl-3-methylfuran-2-yl)pentanoylcarnitine is an acylcarnitine. More specifically, it is an 5-(5-heptyl-3-methylfuran-2-yl)pentanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-(5-heptyl-3-methylfuran-2-yl)pentanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 5-(5-heptyl-3-methylfuran-2-yl)pentanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-(3-Methyl-5-pentylfuran-2-yl)heptanoylcarnitine

3-{[7-(3-methyl-5-pentylfuran-2-yl)heptanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C24H41NO5 (423.29845760000006)


7-(3-Methyl-5-pentylfuran-2-yl)heptanoylcarnitine is an acylcarnitine. More specifically, it is an 7-(3-methyl-5-pentylfuran-2-yl)heptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-(3-Methyl-5-pentylfuran-2-yl)heptanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-(3-Methyl-5-pentylfuran-2-yl)heptanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

8-(5-Pentylfuran-2-yl)octanoylcarnitine

3-{[8-(5-pentylfuran-2-yl)octanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C24H41NO5 (423.29845760000006)


8-(5-Pentylfuran-2-yl)octanoylcarnitine is an acylcarnitine. More specifically, it is an 8-(5-pentylfuran-2-yl)octanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-(5-Pentylfuran-2-yl)octanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 8-(5-Pentylfuran-2-yl)octanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Nervonoyl Glycine

2-(tetracos-15-enamido)acetic acid

C26H49NO3 (423.3712244000001)


N-nervonoyl glycine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Nervonic acid amide of Glycine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Nervonoyl Glycine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Nervonoyl Glycine is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

Gallamonum

2-(2,6-Bis(2-(diethylamino)ethoxy)phenoxy)-N,N-diethylethanamine

C24H45N3O3 (423.34607400000004)


   
   
   

Semiplenamide D

N-(2-methyl-2Z-eicosenoyl)-1S-methyl-2-acetoxyethylamine

C26H49NO3 (423.3712244000001)


   
   

2-(indol-3-yl)ethyl octadeca-9Z,12Z-dienoate

2-(indol-3-yl)ethyl octadeca-9Z,12Z-dienoate

C28H41NO2 (423.31371260000003)


   
   

(6S,7R,10E,14E)-16-(1H-indol-3-yl)-2,6,10,14-tetramethylhexadeca-2,10,14-triene-6,7-diol

(6S,7R,10E,14E)-16-(1H-indol-3-yl)-2,6,10,14-tetramethylhexadeca-2,10,14-triene-6,7-diol

C28H41NO2 (423.31371260000003)


   

N-demethylteleocidin A1|N13-desmethylteleocidin A-1

N-demethylteleocidin A1|N13-desmethylteleocidin A-1

C26H37N3O2 (423.2885622)


   

Linoleyl carnitine

Linoleoyl carnitine;3-carboxy-N,N,N-trimethyl-2-[[(9Z,12Z)-1-oxo-9,12-octadecadienyl]oxy]-1-Propanaminium

C25H45NO4 (423.33484100000004)


   

Linoleyl-carnitine; AIF; CE0; CorrDec

Linoleyl-carnitine; AIF; CE0; CorrDec

C25H45NO4 (423.33484100000004)


   

Linoleyl-carnitine; AIF; CE10; CorrDec

Linoleyl-carnitine; AIF; CE10; CorrDec

C25H45NO4 (423.33484100000004)


   

Linoleyl-carnitine; AIF; CE30; CorrDec

Linoleyl-carnitine; AIF; CE30; CorrDec

C25H45NO4 (423.33484100000004)


   

Linoleyl-carnitine; AIF; CE0; MS2Dec

Linoleyl-carnitine; AIF; CE0; MS2Dec

C25H45NO4 (423.33484100000004)


   

Linoleyl-carnitine; AIF; CE10; MS2Dec

Linoleyl-carnitine; AIF; CE10; MS2Dec

C25H45NO4 (423.33484100000004)


   

Linoleyl-carnitine; AIF; CE30; MS2Dec

Linoleyl-carnitine; AIF; CE30; MS2Dec

C25H45NO4 (423.33484100000004)


   

Linoleyl-carnitine; LC-tDDA; CE10

Linoleyl-carnitine; LC-tDDA; CE10

C25H45NO4 (423.33484100000004)


   

Linoleyl-carnitine; LC-tDDA; CE20

Linoleyl-carnitine; LC-tDDA; CE20

C25H45NO4 (423.33484100000004)


   

Linoleyl-carnitine; LC-tDDA; CE30

Linoleyl-carnitine; LC-tDDA; CE30

C25H45NO4 (423.33484100000004)


   

Linoleyl-carnitine; LC-tDDA; CE40

Linoleyl-carnitine; LC-tDDA; CE40

C25H45NO4 (423.33484100000004)


   

2-Hydroxy-6-pentadecyl-N-phenylbenzamide

2-Hydroxy-6-pentadecyl-N-phenylbenzamide

C28H41NO2 (423.31371260000003)


   

arachidonoyl-(2-phenoxyethyl)amide

N-(2-phenoxy-ethyl)-5Z,8Z,11Z,14Z-eicosatetraenoyl amine

C28H41NO2 (423.31371260000003)


   

Gallamine

Gallamine

C24H45N3O3 (423.34607400000004)


D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents > D009466 - Neuromuscular Blocking Agents M - Musculo-skeletal system > M03 - Muscle relaxants > M03A - Muscle relaxants, peripherally acting agents D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent

   

thio-Miltefosine

1-hexadecyl-thio-phosphorylcholine

C21H46NO3PS (423.2935856000001)


   
   

Octadecadienoylcarnitine

(9Z,12Z)-octadeca-9,12-dienoylcarnitine;3-[(9Z,12Z)-octadeca-9,12-dienoyloxy]-4-(trimethylammonio)butanoate;9cis,12cis-octadecadienoylcarnitine;linoleylcarnitine

C25H45NO4 (423.334841)


   

NA 28:8;O

N-(2-phenoxy-ethyl)-5Z,8Z,11Z,14Z-eicosatetraenoyl amine

C28H41NO2 (423.31371260000003)


   

benzyldimethylstearylammonium chloride

benzyldimethylstearylammonium chloride

C27H50ClN (423.36315700000006)


   

4-methyl-N-octadecylbenzenesulfonamide

4-methyl-N-octadecylbenzenesulfonamide

C25H45NO2S (423.317083)


   

mecetronium etilsulfate

Mecetronium ethylsulfate

C22H49NO4S (423.3382114000001)


C254 - Anti-Infective Agent > C28394 - Topical Anti-Infective Agent

   

lithium 4-[(octadecylamino)carbonyl]benzoate

lithium 4-[(octadecylamino)carbonyl]benzoate

C26H42LiNO3 (423.3324572)


   

O-linoleyl-L-carnitine

O-linoleyl-L-carnitine

C25H45NO4 (423.33484100000004)


An O-octadecadienoyl-L-carnitine where the acyl group specified is linoleyl.

   

8-(5-Pentylfuran-2-yl)octanoylcarnitine

8-(5-Pentylfuran-2-yl)octanoylcarnitine

C24H41NO5 (423.29845760000006)


   

9-(3-Methyl-5-propylfuran-2-yl)nonanoylcarnitine

9-(3-Methyl-5-propylfuran-2-yl)nonanoylcarnitine

C24H41NO5 (423.29845760000006)


   

5-(5-Heptyl-3-methylfuran-2-yl)pentanoylcarnitine

5-(5-Heptyl-3-methylfuran-2-yl)pentanoylcarnitine

C24H41NO5 (423.29845760000006)


   

7-(3-Methyl-5-pentylfuran-2-yl)heptanoylcarnitine

7-(3-Methyl-5-pentylfuran-2-yl)heptanoylcarnitine

C24H41NO5 (423.29845760000006)


   
   
   

(6Z,9Z)-Octadeca-6,9-dienoylcarnitine

(6Z,9Z)-Octadeca-6,9-dienoylcarnitine

C25H45NO4 (423.33484100000004)


   

(2E,4E)-Octadeca-2,4-dienoylcarnitine

(2E,4E)-Octadeca-2,4-dienoylcarnitine

C25H45NO4 (423.33484100000004)


   

(9Z,11E)-Octadeca-9,11-dienoylcarnitine

(9Z,11E)-Octadeca-9,11-dienoylcarnitine

C25H45NO4 (423.33484100000004)


   

(10Z,12Z)-octadeca-10,12-dienoylcarnitine

(10Z,12Z)-octadeca-10,12-dienoylcarnitine

C25H45NO4 (423.33484100000004)


   

3beta-(2-Diethylaminoethoxy)androst-5-en-17-one hydrochloride

3beta-(2-Diethylaminoethoxy)androst-5-en-17-one hydrochloride

C25H42ClNO2 (423.29039020000005)


D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D009676 - Noxae > D000963 - Antimetabolites D004791 - Enzyme Inhibitors

   

cyclopentyl-[(8R,9S,10S)-9-[4-[3-(dimethylamino)prop-1-ynyl]phenyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]methanone

cyclopentyl-[(8R,9S,10S)-9-[4-[3-(dimethylamino)prop-1-ynyl]phenyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]methanone

C26H37N3O2 (423.2885622)


   

cyclopentyl-[(8S,9R,10R)-9-[4-[3-(dimethylamino)prop-1-ynyl]phenyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]methanone

cyclopentyl-[(8S,9R,10R)-9-[4-[3-(dimethylamino)prop-1-ynyl]phenyl]-10-(hydroxymethyl)-1,6-diazabicyclo[6.2.0]decan-6-yl]methanone

C26H37N3O2 (423.2885622)


   

3-Octadeca-9,12-dienoyloxy-4-(trimethylazaniumyl)butanoate

3-Octadeca-9,12-dienoyloxy-4-(trimethylazaniumyl)butanoate

C25H45NO4 (423.33484100000004)


   

N-[(4E,8E)-1,3-dihydroxyicosa-4,8-dien-2-yl]hexanamide

N-[(4E,8E)-1,3-dihydroxyicosa-4,8-dien-2-yl]hexanamide

C26H49NO3 (423.3712244000001)


   

N-[(4E,8E)-1,3-dihydroxytricosa-4,8-dien-2-yl]propanamide

N-[(4E,8E)-1,3-dihydroxytricosa-4,8-dien-2-yl]propanamide

C26H49NO3 (423.3712244000001)


   

N-[(4E,8E)-1,3-dihydroxynonadeca-4,8-dien-2-yl]heptanamide

N-[(4E,8E)-1,3-dihydroxynonadeca-4,8-dien-2-yl]heptanamide

C26H49NO3 (423.3712244000001)


   

N-[(4E,8E)-1,3-dihydroxyhenicosa-4,8-dien-2-yl]pentanamide

N-[(4E,8E)-1,3-dihydroxyhenicosa-4,8-dien-2-yl]pentanamide

C26H49NO3 (423.3712244000001)


   

(Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]heptadec-9-enamide

(Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]heptadec-9-enamide

C26H49NO3 (423.3712244000001)


   

N-[(4E,8E)-1,3-dihydroxyheptadeca-4,8-dien-2-yl]nonanamide

N-[(4E,8E)-1,3-dihydroxyheptadeca-4,8-dien-2-yl]nonanamide

C26H49NO3 (423.3712244000001)


   

N-[(4E,8E)-1,3-dihydroxytetracosa-4,8-dien-2-yl]acetamide

N-[(4E,8E)-1,3-dihydroxytetracosa-4,8-dien-2-yl]acetamide

C26H49NO3 (423.3712244000001)


   

N-[(4E,8E)-1,3-dihydroxydocosa-4,8-dien-2-yl]butanamide

N-[(4E,8E)-1,3-dihydroxydocosa-4,8-dien-2-yl]butanamide

C26H49NO3 (423.3712244000001)


   

(9Z,12Z)-N-(1,3-dihydroxynonan-2-yl)heptadeca-9,12-dienamide

(9Z,12Z)-N-(1,3-dihydroxynonan-2-yl)heptadeca-9,12-dienamide

C26H49NO3 (423.3712244000001)


   

N-[(4E,8E)-1,3-dihydroxyoctadeca-4,8-dien-2-yl]octanamide

N-[(4E,8E)-1,3-dihydroxyoctadeca-4,8-dien-2-yl]octanamide

C26H49NO3 (423.3712244000001)


   

(9Z,12Z)-N-(1,3-dihydroxyoctan-2-yl)octadeca-9,12-dienamide

(9Z,12Z)-N-(1,3-dihydroxyoctan-2-yl)octadeca-9,12-dienamide

C26H49NO3 (423.3712244000001)


   

(Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]octadec-9-enamide

(Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]octadec-9-enamide

C26H49NO3 (423.3712244000001)


   

(Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]tetradec-9-enamide

(Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]tetradec-9-enamide

C26H49NO3 (423.3712244000001)


   

N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]tetradecanamide

N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]tetradecanamide

C26H49NO3 (423.3712244000001)


   

(Z)-N-[(E)-1,3-dihydroxyundec-4-en-2-yl]pentadec-9-enamide

(Z)-N-[(E)-1,3-dihydroxyundec-4-en-2-yl]pentadec-9-enamide

C26H49NO3 (423.3712244000001)


   

(9Z,12Z)-N-(1,3-dihydroxydecan-2-yl)hexadeca-9,12-dienamide

(9Z,12Z)-N-(1,3-dihydroxydecan-2-yl)hexadeca-9,12-dienamide

C26H49NO3 (423.3712244000001)


   

(Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]hexadec-9-enamide

(Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]hexadec-9-enamide

C26H49NO3 (423.3712244000001)


   

N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]decanamide

N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]decanamide

C26H49NO3 (423.3712244000001)


   

N-[(4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]undecanamide

N-[(4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]undecanamide

C26H49NO3 (423.3712244000001)


   

(Z)-N-[(E)-1,3-dihydroxytridec-4-en-2-yl]tridec-9-enamide

(Z)-N-[(E)-1,3-dihydroxytridec-4-en-2-yl]tridec-9-enamide

C26H49NO3 (423.3712244000001)


   

N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]tridecanamide

N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]tridecanamide

C26H49NO3 (423.3712244000001)


   

N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]dodecanamide

N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]dodecanamide

C26H49NO3 (423.3712244000001)


   

(Z)-N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]dodec-5-enamide

(Z)-N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]dodec-5-enamide

C26H49NO3 (423.3712244000001)


   

N-[(2S,3R,4E,6E)-1,3-dihydroxytetradeca-4,6-dien-2-yl]dodecanamide

N-[(2S,3R,4E,6E)-1,3-dihydroxytetradeca-4,6-dien-2-yl]dodecanamide

C26H49NO3 (423.3712244000001)


   

N-[(2S,3R,4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]decanamide

N-[(2S,3R,4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]decanamide

C26H49NO3 (423.3712244000001)


   

N-[(2S,3R,4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]dodecanamide

N-[(2S,3R,4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]dodecanamide

C26H49NO3 (423.3712244000001)


   

N-[(2S,3R,4E,6E)-1,3-dihydroxyhexadeca-4,6-dien-2-yl]decanamide

N-[(2S,3R,4E,6E)-1,3-dihydroxyhexadeca-4,6-dien-2-yl]decanamide

C26H49NO3 (423.3712244000001)


   

(3E)-3-[1-amino-3-methyl-5-[(E)-2-methyltetradec-4-en-6,8-diynyl]pyrrolidin-2-ylidene]-1,5-dimethylpyrrolidine-2,4-dione

(3E)-3-[1-amino-3-methyl-5-[(E)-2-methyltetradec-4-en-6,8-diynyl]pyrrolidin-2-ylidene]-1,5-dimethylpyrrolidine-2,4-dione

C26H37N3O2 (423.2885622)


   

O-linoleoylcarnitine

O-linoleoylcarnitine

C25H45NO4 (423.33484100000004)


An O-acylcarnitine having linoleoyl as the acyl substituent.

   

3-[(9E,12E)-octadeca-9,12-dienoyloxy]-4-(trimethylazaniumyl)butanoate

3-[(9E,12E)-octadeca-9,12-dienoyloxy]-4-(trimethylazaniumyl)butanoate

C25H45NO4 (423.33484100000004)


   

N-(2-phenoxy-ethyl) arachidonoyl amine

N-(2-phenoxy-ethyl) arachidonoyl amine

C28H41NO2 (423.31371260000003)


   

O-octadecadienoylcarnitine

O-octadecadienoylcarnitine

C25H45NO4 (423.33484100000004)


An O-acylcarnitine in which the acyl group specified is octadecadienoyl.

   

O-octadecadienoyl-L-carnitine

O-octadecadienoyl-L-carnitine

C25H45NO4 (423.33484100000004)


An O-acyl-L-carnitine that is L-carnitine having a octadecadienoyl group as the acyl substituent in which the positions of the two double bonds are unspecified.

   

O-linoelaidylcarnitine

O-linoelaidylcarnitine

C25H45NO4 (423.33484100000004)


An O-octadecadienoylcarnitine having linoelaidyl as the acyl substituent.

   

SPHP(21:0)

SPHP(d21:0)

C21H46NO5P (423.31134360000004)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

Cer(26:2)

Cer(d14:2_12:0)

C26H49NO3 (423.3712244000001)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   
   
   
   

NA-Histamine 22:5(7Z,10Z,13Z,16Z,19Z)

NA-Histamine 22:5(7Z,10Z,13Z,16Z,19Z)

C27H41N3O (423.32494560000004)


   
   
   
   
   
   
   
   
   
   
   
   

7-[3,7-dimethyl-9-(1,2,6-trimethylcyclohex-2-en-1-yl)nona-2,6-dien-1-yl]-9-methyl-8h-purin-6-amine

7-[3,7-dimethyl-9-(1,2,6-trimethylcyclohex-2-en-1-yl)nona-2,6-dien-1-yl]-9-methyl-8h-purin-6-amine

C26H41N5 (423.33617860000004)


   

(10s,13s)-5-[(3r)-3,7-dimethylocta-1,6-dien-3-yl]-13-(hydroxymethyl)-10-isopropyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

(10s,13s)-5-[(3r)-3,7-dimethylocta-1,6-dien-3-yl]-13-(hydroxymethyl)-10-isopropyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

C26H37N3O2 (423.2885622)


   

(2e)-n-[(2s)-1-(acetyloxy)propan-2-yl]-2-methylicos-2-enimidic acid

(2e)-n-[(2s)-1-(acetyloxy)propan-2-yl]-2-methylicos-2-enimidic acid

C26H49NO3 (423.3712244000001)


   

7-[(2e,6e)-3,7-dimethyl-9-[(1s,6r)-1,2,6-trimethylcyclohex-2-en-1-yl]nona-2,6-dien-1-yl]-9-methyl-8h-purin-6-amine

7-[(2e,6e)-3,7-dimethyl-9-[(1s,6r)-1,2,6-trimethylcyclohex-2-en-1-yl]nona-2,6-dien-1-yl]-9-methyl-8h-purin-6-amine

C26H41N5 (423.33617860000004)


   

8-(1h-indol-3-ylmethyl)-4,4a,7-trimethyl-8a-(4-methylpent-3-en-1-yl)-hexahydro-1h-naphthalene-1,7-diol

8-(1h-indol-3-ylmethyl)-4,4a,7-trimethyl-8a-(4-methylpent-3-en-1-yl)-hexahydro-1h-naphthalene-1,7-diol

C28H41NO2 (423.31371260000003)


   

3-{[(1s,2r,4ar,4bs,7s,8r,8as,10ar)-7-hydroxy-1,2,4a,8,8a-pentamethyl-decahydro-2h-phenanthren-1-yl]methyl}-1h-indol-6-ol

3-{[(1s,2r,4ar,4bs,7s,8r,8as,10ar)-7-hydroxy-1,2,4a,8,8a-pentamethyl-decahydro-2h-phenanthren-1-yl]methyl}-1h-indol-6-ol

C28H41NO2 (423.31371260000003)


   

n-{2-[(3r,6e)-3,7-dimethyl-9-[(1s,6r)-1,2,6-trimethylcyclohex-2-en-1-yl]nona-1,6-diene-3-sulfonyl]ethyl}guanidine

n-{2-[(3r,6e)-3,7-dimethyl-9-[(1s,6r)-1,2,6-trimethylcyclohex-2-en-1-yl]nona-1,6-diene-3-sulfonyl]ethyl}guanidine

C23H41N3O2S (423.29193260000005)


   

(10s)-10-{2-[(1as,4ar,5s,6s,8as)-1a,5,6-trimethyl-octahydrocyclopropa[e]naphthalen-5-yl]ethyl}-10-methyl-1,3,5,7,9-pentaazatricyclo[6.4.1.0⁴,¹³]trideca-2,4,6,8(13)-tetraen-9-ol

(10s)-10-{2-[(1as,4ar,5s,6s,8as)-1a,5,6-trimethyl-octahydrocyclopropa[e]naphthalen-5-yl]ethyl}-10-methyl-1,3,5,7,9-pentaazatricyclo[6.4.1.0⁴,¹³]trideca-2,4,6,8(13)-tetraen-9-ol

C25H37N5O (423.2997952)


   

n-{2-[3,7-dimethyl-9-(1,2,6-trimethylcyclohex-2-en-1-yl)nona-2,6-diene-1-sulfonyl]ethyl}guanidine

n-{2-[3,7-dimethyl-9-(1,2,6-trimethylcyclohex-2-en-1-yl)nona-2,6-diene-1-sulfonyl]ethyl}guanidine

C23H41N3O2S (423.29193260000005)


   

2-(1h-indol-3-yl)ethyl (9z,12z)-octadeca-9,12-dienoate

2-(1h-indol-3-yl)ethyl (9z,12z)-octadeca-9,12-dienoate

C28H41NO2 (423.31371260000003)


   

n-[1-(acetyloxy)propan-2-yl]-2-methylicos-2-enimidic acid

n-[1-(acetyloxy)propan-2-yl]-2-methylicos-2-enimidic acid

C26H49NO3 (423.3712244000001)


   

(5as,5br,7as,11as,11br,13s,13ar)-2,5b,8,8,11a,13a-hexamethyl-5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-phenanthro[2,1-e]isoindol-13-yl acetate

(5as,5br,7as,11as,11br,13s,13ar)-2,5b,8,8,11a,13a-hexamethyl-5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-phenanthro[2,1-e]isoindol-13-yl acetate

C28H41NO2 (423.31371260000003)


   

(10s)-10-{2-[(1s,2r,4as,8ar)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]ethyl}-10-methyl-1,3,5,7,9-pentaazatricyclo[6.4.1.0⁴,¹³]trideca-2,4,6,8(13)-tetraen-9-ol

(10s)-10-{2-[(1s,2r,4as,8ar)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]ethyl}-10-methyl-1,3,5,7,9-pentaazatricyclo[6.4.1.0⁴,¹³]trideca-2,4,6,8(13)-tetraen-9-ol

C25H37N5O (423.2997952)


   

3-{[(1s,2r,4ar,4br,7s,8r,8ar,10ar)-7-hydroxy-1,2,4a,8,8a-pentamethyl-decahydro-2h-phenanthren-1-yl]methyl}-1h-indol-6-ol

3-{[(1s,2r,4ar,4br,7s,8r,8ar,10ar)-7-hydroxy-1,2,4a,8,8a-pentamethyl-decahydro-2h-phenanthren-1-yl]methyl}-1h-indol-6-ol

C28H41NO2 (423.31371260000003)


   

2,5b,8,8,11a,13a-hexamethyl-5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-phenanthro[2,1-e]isoindol-13-yl acetate

2,5b,8,8,11a,13a-hexamethyl-5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-phenanthro[2,1-e]isoindol-13-yl acetate

C28H41NO2 (423.31371260000003)


   

7-[(2e)-5-[(1s,2r,4ar,8ar)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]-3-methylpent-2-en-1-yl]-9-methyl-8h-purin-6-amine

7-[(2e)-5-[(1s,2r,4ar,8ar)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]-3-methylpent-2-en-1-yl]-9-methyl-8h-purin-6-amine

C26H41N5 (423.33617860000004)


   

(1s,4r,4as,7r,8s,8as)-8-(1h-indol-3-ylmethyl)-4,4a,7-trimethyl-8a-(4-methylpent-3-en-1-yl)-hexahydro-1h-naphthalene-1,7-diol

(1s,4r,4as,7r,8s,8as)-8-(1h-indol-3-ylmethyl)-4,4a,7-trimethyl-8a-(4-methylpent-3-en-1-yl)-hexahydro-1h-naphthalene-1,7-diol

C28H41NO2 (423.31371260000003)


   

n-{2-[3,7-dimethyl-9-(1,2,6-trimethylcyclohex-2-en-1-yl)nona-1,6-diene-3-sulfonyl]ethyl}guanidine

n-{2-[3,7-dimethyl-9-(1,2,6-trimethylcyclohex-2-en-1-yl)nona-1,6-diene-3-sulfonyl]ethyl}guanidine

C23H41N3O2S (423.29193260000005)


   

(10s)-10-{2-[(1s,2r,4ar,8as)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]ethyl}-10-methyl-1,3,5,7,9-pentaazatricyclo[6.4.1.0⁴,¹³]trideca-2,4,6,8(13)-tetraen-9-ol

(10s)-10-{2-[(1s,2r,4ar,8as)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]ethyl}-10-methyl-1,3,5,7,9-pentaazatricyclo[6.4.1.0⁴,¹³]trideca-2,4,6,8(13)-tetraen-9-ol

C25H37N5O (423.2997952)


   

n-{2-[(2e,6e)-3,7-dimethyl-9-[(1s,6r)-1,2,6-trimethylcyclohex-2-en-1-yl]nona-2,6-diene-1-sulfonyl]ethyl}guanidine

n-{2-[(2e,6e)-3,7-dimethyl-9-[(1s,6r)-1,2,6-trimethylcyclohex-2-en-1-yl]nona-2,6-diene-1-sulfonyl]ethyl}guanidine

C23H41N3O2S (423.29193260000005)


   

3-[(7-hydroxy-1,2,4a,8,8a-pentamethyl-decahydro-2h-phenanthren-1-yl)methyl]-1h-indol-6-ol

3-[(7-hydroxy-1,2,4a,8,8a-pentamethyl-decahydro-2h-phenanthren-1-yl)methyl]-1h-indol-6-ol

C28H41NO2 (423.31371260000003)


   

n-{2-[(6e)-3,7-dimethyl-9-(1,2,6-trimethylcyclohex-2-en-1-yl)nona-1,6-diene-3-sulfonyl]ethyl}guanidine

n-{2-[(6e)-3,7-dimethyl-9-(1,2,6-trimethylcyclohex-2-en-1-yl)nona-1,6-diene-3-sulfonyl]ethyl}guanidine

C23H41N3O2S (423.29193260000005)


   

16-(1h-indol-3-yl)-2,6,10,14-tetramethylhexadeca-2,10,14-triene-6,7-diol

16-(1h-indol-3-yl)-2,6,10,14-tetramethylhexadeca-2,10,14-triene-6,7-diol

C28H41NO2 (423.31371260000003)


   

(10s)-10-{2-[(1s,2r,4ar,8ar)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]ethyl}-10-methyl-1,3,5,7,9-pentaazatricyclo[6.4.1.0⁴,¹³]trideca-2,4,6,8(13)-tetraen-9-ol

(10s)-10-{2-[(1s,2r,4ar,8ar)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]ethyl}-10-methyl-1,3,5,7,9-pentaazatricyclo[6.4.1.0⁴,¹³]trideca-2,4,6,8(13)-tetraen-9-ol

C25H37N5O (423.2997952)


   

5-(3,7-dimethylocta-1,6-dien-3-yl)-13-(hydroxymethyl)-10-isopropyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

5-(3,7-dimethylocta-1,6-dien-3-yl)-13-(hydroxymethyl)-10-isopropyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

C26H37N3O2 (423.2885622)


   

n-{2-[(2e,6e)-3,7-dimethyl-9-(1,2,6-trimethylcyclohex-2-en-1-yl)nona-2,6-diene-1-sulfonyl]ethyl}guanidine

n-{2-[(2e,6e)-3,7-dimethyl-9-(1,2,6-trimethylcyclohex-2-en-1-yl)nona-2,6-diene-1-sulfonyl]ethyl}guanidine

C23H41N3O2S (423.29193260000005)


   

2-(1h-indol-3-yl)ethyl octadeca-9,12-dienoate

2-(1h-indol-3-yl)ethyl octadeca-9,12-dienoate

C28H41NO2 (423.31371260000003)